173 related articles for article (PubMed ID: 16000961)
21. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients.
de Vries IJ; Lesterhuis WJ; Scharenborg NM; Engelen LP; Ruiter DJ; Gerritsen MJ; Croockewit S; Britten CM; Torensma R; Adema GJ; Figdor CG; Punt CJ
Clin Cancer Res; 2003 Nov; 9(14):5091-100. PubMed ID: 14613986
[TBL] [Abstract][Full Text] [Related]
22. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
[TBL] [Abstract][Full Text] [Related]
23. Vaccination with melanoma lysate-pulsed dendritic cells, of patients with advanced colorectal carcinoma: report from a phase I study.
Burgdorf SK; Fischer A; Claesson MH; Kirkin AF; Dzhandzhugazyan KN; Rosenberg J
J Exp Clin Cancer Res; 2006 Jun; 25(2):201-6. PubMed ID: 16918131
[TBL] [Abstract][Full Text] [Related]
24. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients.
Rahma OE; Ashtar E; Czystowska M; Szajnik ME; Wieckowski E; Bernstein S; Herrin VE; Shams MA; Steinberg SM; Merino M; Gooding W; Visus C; Deleo AB; Wolf JK; Bell JG; Berzofsky JA; Whiteside TL; Khleif SN
Cancer Immunol Immunother; 2012 Mar; 61(3):373-84. PubMed ID: 21927947
[TBL] [Abstract][Full Text] [Related]
25. Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen.
Smithers M; O'Connell K; MacFadyen S; Chambers M; Greenwood K; Boyce A; Abdul-Jabbar I; Barker K; Grimmett K; Walpole E; Thomas R
Cancer Immunol Immunother; 2003 Jan; 52(1):41-52. PubMed ID: 12536239
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines.
Asai T; Storkus WJ; Whiteside TL
Clin Diagn Lab Immunol; 2000 Mar; 7(2):145-54. PubMed ID: 10702485
[TBL] [Abstract][Full Text] [Related]
27. Peptide vaccination in Montanide adjuvant induces and GM-CSF increases CXCR3 and cutaneous lymphocyte antigen expression by tumor antigen-specific CD8 T cells.
Clancy-Thompson E; King LK; Nunnley LD; Mullins IM; Slingluff CL; Mullins DW
Cancer Immunol Res; 2013 Nov; 1(5):332-9. PubMed ID: 24377099
[TBL] [Abstract][Full Text] [Related]
28. Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells.
Fay JW; Palucka AK; Paczesny S; Dhodapkar M; Johnston DA; Burkeholder S; Ueno H; Banchereau J
Cancer Immunol Immunother; 2006 Oct; 55(10):1209-18. PubMed ID: 16331519
[TBL] [Abstract][Full Text] [Related]
29. A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor-dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2.
Greene JM; Schneble EJ; Jackson DO; Hale DF; Vreeland TJ; Flores M; Martin J; Herbert GS; Hardin MO; Yu X; Wagner TE; Peoples GE
Cancer Immunol Immunother; 2016 Apr; 65(4):383-92. PubMed ID: 26894495
[TBL] [Abstract][Full Text] [Related]
30. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer.
Chianese-Bullock KA; Irvin WP; Petroni GR; Murphy C; Smolkin M; Olson WC; Coleman E; Boerner SA; Nail CJ; Neese PY; Yuan A; Hogan KT; Slingluff CL
J Immunother; 2008 May; 31(4):420-30. PubMed ID: 18391753
[TBL] [Abstract][Full Text] [Related]
31. Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy.
Engelhard VH; Bullock TN; Colella TA; Sheasley SL; Mullins DW
Immunol Rev; 2002 Oct; 188():136-46. PubMed ID: 12445287
[TBL] [Abstract][Full Text] [Related]
32. A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma.
Pullarkat V; Lee PP; Scotland R; Rubio V; Groshen S; Gee C; Lau R; Snively J; Sian S; Woulfe SL; Wolfe RA; Weber JS
Clin Cancer Res; 2003 Apr; 9(4):1301-12. PubMed ID: 12684398
[TBL] [Abstract][Full Text] [Related]
33. Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: a randomized phase I trial in patients with metastatic melanoma and renal cell carcinoma.
Smith II JW; Kurt RA; Baher AG; Denman S; Justice L; Doran T; Gilbert M; Alvord WG; Urba WJ
J Immunother; 2003; 26(2):130-8. PubMed ID: 12616104
[TBL] [Abstract][Full Text] [Related]
34. Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901.
Roberts JD; Niedzwiecki D; Carson WE; Chapman PB; Gajewski TF; Ernstoff MS; Hodi FS; Shea C; Leong SP; Johnson J; Zhang D; Houghton A; Haluska FG;
J Immunother; 2006; 29(1):95-101. PubMed ID: 16365605
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report.
Dillman RO; Selvan SR; Schiltz PM; McClay EF; Barth NM; DePriest C; de Leon C; Mayorga C; Cornforth AN; Allen K
Cancer Biother Radiopharm; 2009 Jun; 24(3):311-9. PubMed ID: 19538053
[TBL] [Abstract][Full Text] [Related]
36. Active specific immunotherapy of melanoma with a GM3 ganglioside-based vaccine: a report on safety and immunogenicity.
Guthmann MD; Bitton RJ; Carnero AJ; Gabri MR; Cinat G; Koliren L; Lewi D; Fernandez LE; Alonso DF; Gómez DE; Fainboim L
J Immunother; 2004; 27(6):442-51. PubMed ID: 15534488
[TBL] [Abstract][Full Text] [Related]
37. Cytotoxic T cell induction against human malignant melanoma cells using HLA-A24-restricted melanoma peptide cocktail.
Akiyama Y; Maruyama K; Nara N; Mochizuki T; Yamamoto A; Yamazaki N; Kawashima I; Nukaya I; Takesako K; Yamaguchi K
Anticancer Res; 2004; 24(2B):571-7. PubMed ID: 15160996
[TBL] [Abstract][Full Text] [Related]
38. gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells.
Walker EB; Haley D; Miller W; Floyd K; Wisner KP; Sanjuan N; Maecker H; Romero P; Hu HM; Alvord WG; Smith JW; Fox BA; Urba WJ
Clin Cancer Res; 2004 Jan; 10(2):668-80. PubMed ID: 14760090
[TBL] [Abstract][Full Text] [Related]
39. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
40. Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases.
Panelli MC; Riker A; Kammula U; Wang E; Lee KH; Rosenberg SA; Marincola FM
J Immunol; 2000 Jan; 164(1):495-504. PubMed ID: 10605047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
